ORAMED PHARMACEUTICALS INC.: 10-Q filed 2012-01-12

Name: ORAMED PHARMACEUTICALS INC.: 10-Q filed 2012-01-12
Creator: ORAMED PHARMACEUTICALS INC.

What ORAMED PHARMACEUTICALS INC. reported in its quarterly report filed 2012-01-12 (fiscal Q1 2012): 24 published measures, 63 facts as tagged in accession 0001178913-12-000118.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-01-12
Fiscal period: fiscal Q1 2012
Accession: 0001178913-12-000118 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ORAMED PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-11-30	3,902,577	USD
At 2011-08-31	4,325,937	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2011-11-30	3,317,388	USD
At 2011-08-31	3,723,916	USD
At 2010-08-31	830,272	USD
At 2009-08-31	2,746,192	USD
At 2002-04-11	53,700	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2011-11-30	1,495,615	USD
At 2011-08-31	1,513,365	USD
At 2010-11-30	1,101,283	USD
At 2010-08-31	1,199,638	USD
At 2009-08-31	1,716,866	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	-478,519	USD	91
2002-04-12 to 2011-11-30	-15,025,802	USD	3520
2010-09-01 to 2011-08-31	-1,561,245	USD	365
2010-09-01 to 2010-11-30	-602,784	USD	91
2002-04-12 to 2010-08-31	-12,986,038	USD	3064

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	-466,689	USD	91
2002-04-12 to 2011-11-30	-9,010,654	USD	3520
2010-09-01 to 2010-11-30	-498,355	USD	91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2002-04-12 to 2011-11-30	123,483	USD	3520

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2002-04-12 to 2011-11-30	12,002,997	USD	3520
2010-09-01 to 2010-11-30	300,000	USD	91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	448,939	USD	91
2002-04-12 to 2011-11-30	-1,496,728	USD	3520
2010-09-01 to 2010-11-30	100,000	USD	91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2011-11-30	-15,025,802	USD
At 2011-08-31	-14,547,299	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2002-04-12 to 2011-11-30	150,558	USD	3520

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2011-11-30	11,334	USD
At 2011-08-31	17,376	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	51,296	USD	91
2002-04-12 to 2011-11-30	4,751,425	USD	3520
2010-09-01 to 2010-11-30	195,301	USD	91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	-465,917	USD	91
2002-04-12 to 2011-11-30	-15,711,025	USD	3520
2010-09-01 to 2010-11-30	-601,617	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-11-30	3,865,484	USD
At 2011-08-31	4,284,082	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-11-30	424,372	USD
At 2011-08-31	441,292	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2011-11-30	86,000	USD
At 2011-08-31	542,891	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	184,016	USD	91
2002-04-12 to 2011-11-30	8,035,865	USD	3520
2010-09-01 to 2010-11-30	286,488	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2011-11-30	70,104,583	shares
At 2011-08-31	70,104,583	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2011-11-30	-4,221	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	-478,519	USD	91
2002-04-12 to 2011-11-30	-14,875,244	USD	3520
2010-09-01 to 2010-11-30	-602,784	USD	91

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	-4,205	USD	91
2002-04-12 to 2010-08-31	-16	USD	3064

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	281,901	USD	91
2002-04-12 to 2011-11-30	7,240,284	USD	3520
2010-09-01 to 2010-11-30	315,129	USD	91

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	6,042	USD	91
2002-04-12 to 2011-11-30	112,149	USD	3520
2010-09-01 to 2010-11-30	7,451	USD	91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2011-09-01 to 2011-11-30	-16,920	USD	91
2002-04-12 to 2011-11-30	377,120	USD	3520
2010-09-01 to 2010-11-30	-76,182	USD	91

Inspect the source

Entity: ORAMED PHARMACEUTICALS INC. / CIK 0001176309
Captured: 2026-09-20T07:44:51.277Z
SEC response SHA-256: 4de2fa61f6e99a9334450df93c3a54e105e138fae12a8b631b4bdc95f4c98422

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001176309.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))